Navigation Links
Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives
Date:2/20/2008

The MAA is being reviewed under the EMEA's centralized procedure. An authorization from the EMEA would apply to all 27 European Union member states, as well as Norway and Iceland.

The decrease in revenue from collaboration agreement for the current periods compared to the same periods in the previous year is mainly attributable to a change in the estimated period over which the non-refundable upfront payment received from Centocor in respect of eprodisate (KIACTA(TM)) is being amortized.

Reimbursable costs revenue amounted to $64,000 for the current quarter ($396,000 for the year), compared to $178,000 for the same period in the previous year ($712,000 for the year) and consists of costs reimbursable by Centocor in respect of eprodisate (KIACTA(TM))-related activities. The Company earns no margin on these reimbursable costs.

Research and development expenses, before research tax credits and grants, amounted to $12,199,000 for the current quarter ($55,732,000 for the year), compared to $14,142,000 for the same period in the previous year ($51,688,000 for the year). The decrease in the current quarter compared to the same period the previous year is mainly attributable to a reduction in expenses incurred in relation to the development of tramiprosate (ALZHEMED(TM)), primarily in respect of the North American Phase III clinical trial. Also, during the second quarter of 2007, the workforce was reduced due to delay encountered in the product candidate development programs. The increase in the current year compared to the same period the previous year is due to expenses incurred in relation to the development of tramiprosate (ALZHEMED(TM)), primarily in respect of the Phase III clinical trial in Europe and the North American open-label extension of the Phase III study, as well as the conduct of a QT cardiac status Phase I study. For the year ended December 31, 2007, research and development expenses also included costs incurred to support the North A
'/>"/>

SOURCE NEUROCHEM INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine news :

1. Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live
2. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
3. Neurochem to present at JPMorgan Healthcare Conference
4. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
5. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
6. Neurochem announces departure of Dr. Philippe Calais, President, Global Business
7. Neurochem reports results for third quarter of fiscal 2007
8. Emageon Reports Fourth Quarter and 2007 Financial Results
9. Cyberonics Reports Operating Profit for Third Quarter FY08 and Announces Share Repurchase Program
10. Platinum Underwriters Holdings, Ltd. Reports Record Fourth Quarter and Year Ended December 31, 2007 Financial Results
11. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... (PRWEB) December 26, 2014 Cooking ... of 3.1 out of 5. This score reflects slightly ... level of product specialization, low switching costs and a ... reduced by the low availability of substitutes for cooking ... price of steel and aluminum, key inputs in the ...
(Date:12/26/2014)... “Many people become overwhelmed by the thought ... and phone calls with insurance companies,” The Jones Firm ... free eBook on pedestrian and bicycle accidents . ... bicycle auto accident claims assures the injured individual that ... handling their case while they focus on recovering. ...
(Date:12/26/2014)... (PRWEB) December 26, 2014 Parker ... for the best in heating, cooling and plumbing ... 24 hour emergency services in 2014 with regard ... know that Arizona is known for its incredibly ... that understands the intricacies and details of a ...
(Date:12/25/2014)... 26, 2014 The report “Nintedanib ... 2023” focuses on the current treatment landscape, unmet ... colorectal cancer market. Stivarga is a drug which ... rectal cancer. Boehringer Ingelheim is developing nintedanib (BIBF-1120), ... of refractory CRC in the US, Europe, and ...
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of wedding dresses ... selection of black one-shoulder cocktail dresses . In addition, ... available at discounted prices, up to 70% off. ... three weeks only. You know, we have thousands of frequent ... our new items can visit our website for more details. ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2
... of adults , , MONDAY, Aug. 18 (HealthDay News) -- Teens ... the risk of elevated blood pressure, a new study finds. ... said study senior author Dr. Susan Redline, director of the ... Cleveland. , "In adults, there has been evidence that less ...
... a Phase II Early Career Award from the Wallace H. ... device that uses light to detect skin cancer without the ... will support Tunnell,s work for the next two years to ... additional clinical trials. He previously received one of 23 Phase ...
... Shows Alarming Trends in Cosmetic Surgery and Health Risks ... ... YWCA USA today released a new,report that reveals the impact of ... and interpersonal,relationships of American women and girls. The report, Beauty at ...
... Care,Initiatives (ECI - HC Innovations, Inc., OTC Bulletin ... two year contract with HIP Health Plans of,New ... practices into,Medical Homes. The contract is part of ... improved care for health plan members by,developing a ...
... close-up views of how strands interact could be key, researchers ... frizzy or flyaway, nearly everyone puts up with an unruly ... trained their microscopes on hair to find out why it ... new study, said to be the first of its kind, ...
... 18 The American Medical,Association (AMA) Foundation awarded ... Jodie Totten, who grew up in Sitka, Alaska ... Totten will receive a,$5,000 scholarship to help defray ... annually supports a medical student who graduated,from a ...
Cached Medicine News:Health News:Poor Sleep Linked to High Blood Pressure in Teens 2Health News:Poor Sleep Linked to High Blood Pressure in Teens 3Health News:New probe to detect skin cancer receives more funding for clinical trials 2Health News:America's Beauty Obsession Poses Serious Consequences for Women and Girls, Report Reveals 2Health News:Enhanced Care Initiatives (HC Innovations, Inc.) Contracts with HIP and GHI to Create a Medical Home Network Project with Support from the Commonwealth Fund 2Health News:Enhanced Care Initiatives (HC Innovations, Inc.) Contracts with HIP and GHI to Create a Medical Home Network Project with Support from the Commonwealth Fund 3Health News:Enhanced Care Initiatives (HC Innovations, Inc.) Contracts with HIP and GHI to Create a Medical Home Network Project with Support from the Commonwealth Fund 4Health News:Science May Banish Bad Hair Days 2Health News:AMA Foundation Presents the Arthur N. Wilson, MD Scholarship to Promising Medical Student From Southeast Alaska 2
(Date:12/24/2014)... 24, 2014 LifeScienceIndustryResearch.com ... Disposable Syringe Industry of 178 pages providing ... intelligence library. The 2014 Market ... is a professional and deep research report ... analysis, the report introduces Disposable Syringe basic ...
(Date:12/24/2014)... Dec. 23, 2014  The American Diabetes Association ... target for people with diabetes and that all ... doses of statins, in keeping with recent changes ... the American College of Cardiology (ACC) and American ... the most recent changes to the Association,s annual ...
(Date:12/24/2014)... HILL, N.C. , Dec. 23, 2014  Medical ... success. As the key link between the medical device ... grow even more in the coming years as the ... According to research by benchmarking firm, ... MSLs can gain an important edge is by harnessing ...
Breaking Medicine Technology:World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4Role of Medical Science Liaisons Evolving in Medical Device Sector 2
... BATESVILLE, Ind. , May 26 Hill-Rom Holdings, Inc., ... Greg Miller , senior vice president and chief financial officer, Hill-Rom.  He ... York City on Wednesday, June 9, 2010 , at 1:30 ... , You ...
... 26 Today, Pfizer Inc. (NYSE: PFE ... Research and Development, as the Company completes its integration of ... Wyeth,s Research and Development organization from May 2008 , ... President of Pfizer,s BioTherapeutics Research & Development.  Prior to his ...
Cached Medicine Technology:Hill-Rom to Present at the Jefferies Global Life Sciences Conference 2Pfizer Appoints Mikael Dolsten President of Worldwide Research and Development 2Pfizer Appoints Mikael Dolsten President of Worldwide Research and Development 3Pfizer Appoints Mikael Dolsten President of Worldwide Research and Development 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: